title: Antibody-targeted nanoparticles for cancer treatment.
abstract: Nanoparticles (NPs) are diverse and versatile with physical properties that can be employed for use in cancer medicine. Targeting NPs using antibodies and antibody fragments could overcome some of the limitations seen with current targeted therapies. This review will discuss the role of antibody-targeted NPs in the treatment of cancer: as delivery vehicles, targeted theranostic agents and in the evolving field of cancer hyperthermia.
authors.affiliation: UCL Cancer Institute, University College London, London, UK.
authors.forename: Thomas
authors.initials: T
authors.lastname: Carter
authors.affiliation: UCL Cancer Institute, University College London, London, UK.|University College London Hospitals NHS Foundation Trust, London, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Mulholland
authors.affiliation: UCL Cancer Institute, University College London, London, UK.
authors.forename: Kerry
authors.initials: K
authors.lastname: Chester
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans; D006979:Hyperthermia, Induced; D058990:Molecular Targeted Therapy; D053758:Nanoparticles; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D057127:Single-Chain Antibodies / Q000627:therapeutic use*; D000068936:Theranostic Nanomedicine
chemical_list: D000906:Antibodies; D052157:Aptamers, Nucleotide; D057127:Single-Chain Antibodies; D005492:Folic Acid
keywords: antibodies; cancer treatment; clinical translation; hyperthermia; nanoparticles; targeting; theranostics